Impact of Iron Deficiency on Clinical Outcomes in Congestive Heart Failure: A Retrospective Analysis of Risk Stratification and Mortality

Abstract

Introduction
Iron deficiency frequently coexists with congestive heart failure, thereby increasing morbidity and mortality. Although guidelines typically define iron deficiency as ferritin under 100 ng/mL or 100–299 ng/mL plus transferrin saturation below 20%, precise stratification remains elusive. Intravenous iron therapy has demonstrated benefits, yet clear delineations for deficiency, adequacy, and hyperferritinemia are lacking.

Aim
This study aims to compare a machine learning–devised model vs. a clinically based model in predicting time-to-event outcomes in CHF, refining risk stratification when compared to current iron deficiency guidelines.

Material and Methods
A retrospective design included adults aged 18–89 with congestive heart failure hospitalized for at least one day, with iron panels obtained within 24 hours of admission. Electronic data were gathered by text-mining and standard record searches. Kolmogorov–Smirnov guided normality checks, and parametric or nonparametric tests were selected accordingly. Kaplan–Meier analysis and Cox regression assessed one-year mortality. The machine learning model ("final category tertile") defined T1 as ferritin below 100 ng/mL or 100–299 ng/mL with transferrin saturation under 20%, T2 as ferritin 100–299 ng/mL with transferrin saturation 20% or higher, and T3 as ferritin above 300 ng/mL. The clinically based ferritin custom tertile model comprised T1: ferritin below 100 ng/mL, T2: ferritin 100–299 ng/mL, and T3: ferritin 300 ng/mL or above. Covariates such as age, shock, malignancy, eGFR, and other factors were included in multivariable models ($\alpha=0.05$).

Results
Univariate Cox analyses indicated stronger hazard separation with the machine learning approach than with simpler, binary criteria as current guidelines suggest ($p<0.001$). T3 (hyperferritinemia) showed an increased mortality risk relative to T1, with T2 in an intermediate range. Multivariable models preserved the robust discriminative power of the machine learning–based strategy (T3 hazard ratio ≈1.84). Although the ferritin custom tertile classification was also significant (T3 hazard ratio ≈1.48), slightly lower early sensitivity was observed. Additional findings suggested that iron supplementation reduced hazard in deficiency strata, reinforcing the importance of precise categorization.

Conclusion
Refined iron-status stratification appears pivotal for risk assessment in congestive heart failure. The machine learning–based model provided clearer identification of high-risk subsets than standard cutoffs, differentiating deficiency, adequacy, and potential overload. Prospective validation may support adoption of nuanced models, enhance management strategies, and potentially reduce adverse outcomes.

Abdulla Hourani, Medical University of Warsaw

Arman David Sürmeli, Medical University of Warsaw

Introduction

Iron deficiency (ID) is a significant global public health concern and affects a substantial proportion of patients with congestive heart failure (CHF), with estimates suggesting that as many as 50%–80% of individuals with chronic heart failure may be iron deficient [1]. While anemia can often be present in this population, evidence shows that ID itself can adversely influence outcomes—even in the absence of anemia—by contributing to poor exercise tolerance, diminished health-related quality of life (HRQoL) [2,3], and increased risks of hospitalization and mortality. Recognizing the central role of ID in exacerbating congestive heart failure symptoms, the European Society of Cardiology (ESC) has formally acknowledged iron deficiency as an important comorbidity and now recommends routine testing of iron status, including transferrin saturation (TSAT) and serum ferritin, for all newly diagnosed heart failure patients [4].

Multiple large-scale trials and meta-analyses have consistently highlighted the clinical benefits of correcting iron deficiency in CHF. In particular, intravenous (IV) iron supplementation—most notably ferric carboxymaltose (FCM)—has been shown to alleviate symptoms, improve exercise capacity, and reduce heart failure–related hospitalizations [4-7]. Observational and randomized evidence further indicates that these advantages extend beyond anemic patients to those whose hemoglobin levels remain within normal limits but whose low TSAT (<20%) nonetheless signals depleted functional iron stores [5,8]. This distinction reflects the importance of assessing iron parameters as a distinct therapeutic target in heart failure management, rather than relying on hemoglobin alone.

Despite these findings, there remains no universally accepted definition of iron deficiency in CHF, as cutoff values for ferritin and TSAT vary among studies, creating a lack of standardization that complicates the interpretation of ID prevalence, influencing patient therapy outcomes [1,9]. Many clinical investigations define ID according to a serum ferritin <100 μg/L, or 100–299 μg/L in combination with a TSAT <20%, whereas other research has included thresholds of TSAT <15% or even <30%, depending on population characteristics [10]. Such variability complicates prevalence estimates and can influence patient selection for iron therapy trials, highlighting the need for standardized methods of diagnosing ID in this setting. Nonetheless, the prevailing consensus is that ID—irrespective of anemia—plays a key pathophysiological role by impairing mitochondrial function, promoting unfavorable cardiac remodeling, and triggering inflammatory processes that further compromise cardiac output [11]. Improvements seen with IV iron administration include better left ventricular function indices, enhanced functional status as measured by 6-minute walk tests, and reductions in the rate of cardiovascular (CV) death or readmission for worsening congestive heart failure [5,8]. Oral iron supplementation, on the other hand, has generally not demonstrated consistent benefits in CHF, largely due to poor absorption and intolerability in this population [11].

In light of the above, this study focuses on further clarifying the effects and optimal diagnostic criteria of iron deficiency anemia in congestive heart failure. By exploring how ID influences clinical progression, exercise performance, and patient-reported outcomes—alongside evaluating the impact of iron supplementation strategies—this research aims to address the ongoing need for clearer, evidence-based guidelines on screening and treating ID in CHF. Such insights will ultimately contribute to improving quality of life and reducing the considerable burden of recurrent hospitalizations and mortality faced by heart failure patients worldwide.

Methodology

Study Design and Setting

A retrospective observational study design was implemented, focusing on adult patients with congestive heart failure (CHF) who were admitted for at least one day, over the course of a year. Electronic medical record (EMR) data, clinical notes, and laboratory values were extracted and merged for analysis. Admissions were included if ICD documentation confirmed CHF (supported by clinical notes or imaging), iron testing (ferritin, iron, TIBC, or transferrin) was performed within 24 hours of admission, and only the first hospitalization in the study window was retained. Records with over 30% missing critical data or with an inpatient length of stay under one day were excluded.

Patient Selection

Inclusion criteria were met by 1839 patients aged >18 and <89 years, with validated ICD diagnoses of CHF and accessible iron parameter measurements within the first 24 hours, collected from MIMIC-IV, a public database from the Beth Israel Deaconess Medical Center, containing electronic health records. Exclusion criteria encompassed absent iron-related tests, missingness above 30% of essential labs, and inconsistent or erroneous timestamps. Clinical notes were analyzed using multiple text-mining and large language model methodologies (R1 70B, GPT-O1, and optical character recognition with regex) to generate and verify CHF diagnoses and ejection fraction categories. Demographic and clinical variables (e.g., age, sex, comorbidities including shock, malignancy, renal disease, as well as ICU stay and ejection fraction status) were collected from structured EMR fields and supplemented by natural language processing. Laboratory measurements for ferritin, iron, total iron-binding capacity (TIBC), transferrin saturation (TSAT), hemoglobin, and other routine labs (e.g., creatinine for eGFR calculation) were obtained from the first tests within 24 hours of admission.

Definition of Iron Deficiency

Iron deficiency (ID) was defined using guideline-based thresholds of ferritin <100 ng/mL or ferritin 100–299 ng/mL with TSAT <20% [12]. Additional custom ferritin categories were examined to evaluate the possibility of iron overload or normal status.

Data Cleaning and Categorization

All relevant continuous variables underwent normality checks (kurtosis, skewness, Kolmogorov–Smirnov, and Anderson–Darling). Non-normally distributed variables were either log-transformed (e.g., log ferritin) or categorized into tertiles or quartiles. Missing data were assessed using Little's MCAR test, and rows with ≥30% missing in critical labs were removed. Data that appeared non-randomly missing were excluded. Patients were grouped by guideline-defined IDA versus non-IDA, a clinically distribution–based ferritin custom tertile model, TSAT tertiles, and a combined ferritin TSAT–tertile machine learning–devised model . These categories were used to analyze how distinct levels of iron parameters might relate to clinical outcomes.

Statistical Analyses

Parametric or nonparametric tests (t-tests, ANOVA, Wilcoxon, Kruskal–Wallis) were performed, based on distributional assessments. Time-to-event outcomes (90-day, 180-day, 365-day mortality) were then evaluated with Kaplan–Meier survival curves and Cox proportional hazards models. Age, sex, hemoglobin, ejection fraction category, and comorbidities (e.g., chronic kidney disease, cancer, shock) were included as covariates. Model assumptions were verified by Schoenfeld residuals, ferritin was log-transformed when indicated, and TIBC/TSAT were examined both as

continuous and as categorized variables. Interaction terms were tested if clinically plausible. Sensitivity analyses excluded patients without early iron measurements, re-ran models for those with partial ICD documentation, and adjusted for potential confounding due to oral or IV iron therapy.

Ethical Considerations

The dataset was de-identified, and informed consent was waived by the institutional review board due to the retrospective nature of the analysis. Overall, ID was defined both by guideline criteria and by custom threshold categorizations, with missingness addressed through Little's MCAR test and listwise deletion if over 30% of critical data were absent, followed by survival analyses to explore mortality risk associated with iron deficiency anemia in hospitalized CHF patients.

Results

Kaplan–Meier survival curves and Cox proportional hazards models were generated to assess mortality risk at 90, 180, and 365 days in patients with congestive heart failure (CHF). The analyses focused on three iron-status definitions. The first was the guidelines–based model definition, which classified iron deficiency using ferritin <100 ng/mL or ferritin 100–299 ng/mL with transferrin saturation (TSAT) <20%. The second was clinically distribution–based model, which divided patients into three groups based on ferritin and TSAT cutoffs (<100 ng/mL plus TSAT <20%, ≥300 ng/mL, or 100–299 ng/mL plus TSAT >20%). The third was a machine learning–devised model, which included three categories: iron deficiency (ferritin <100 ng/mL or ferritin 100–299 ng/mL with TSAT <20%), high ferritin (≥300 ng/mL), and normative values (ferritin 100–299 ng/mL plus TSAT >20%). All analyses adjusted for age, sex, admission to intensive care, ejection fraction category, comorbidities (shock, malignancy, renal disease), and hemoglobin. Separate curves and tables illustrated hazard ratios (HRs) for mortality under each iron-status definition. Additional graphs were created for serum iron, total iron-binding capacity (TIBC), ferritin, and TSAT distributions, which were tested for normality and divided into tertiles or quartiles for preliminary examinations of their relationships with mortality.

The guidelines–based model criteria served as the baseline comparator. Univariate analyses found that iron deficiency defined by these cutoffs carried an approximate HR of 2.48 ($p<0.001$) for mortality. In fully adjusted Cox models labeled "guidelines–based model 1," "guidelines–based model 2," and "guidelines–based model 3," the presence of iron deficiency remained a strong predictor of death at 90, 180, and 365 days (HR 2.41 [95%CI 1.97–2.96], HR 2.86 [95%CI2.28–3.58], and HR 3.05 [95%CI 2.42–3.85], all $p=0.000$). Older age, intensive care admission, lower hemoglobin, shock, and malignancy were significant covariates across these models. Patients who met guideline criteria showed a steeper decline in Kaplan–Meier survival estimates, indicating that the guidelines–based binary approach reliably differentiated higher-risk individuals. Tables summarizing patient characteristics and univariate models revealed that lower hemoglobin consistently corresponded to elevated risk, reflected in HR values near 0.94–0.95 per unit increase in hemoglobin. Poor renal function (captured by lower eGFR or dialysis requirement) was also associated with higher mortality hazard in most analyses. Shock had HR estimates around 2.0, while ICU stay ranged from 1.48 to slightly above 2.0, delineating the adverse consequences of critical illness. The presence of both iron deficiency and comorbidities (shock, malignant disease, chronic kidney impairment) was frequently linked to higher short- and mid-term mortality. A second scheme, the clinically distribution–based model, grouped participants into <100 ng/mL ferritin plus TSAT <20%, ≥300 ng/mL ferritin, and 100–299 ng/mL ferritin plus TSAT >20%. Stepwise increases in mortality risk emerged across these categories. One model ("clinically distribution–based model 1") produced an HR of 1.49 (1.19–1.87, $p=0.001$) for the intermediate group (100–299 ng/mL plus TSAT>20%) and

1.95 (1.35–2.82, p=0.000) for those at or above 300 ng/mL. Another version ("clinically distribution–based model 3") showed HRs of 1.35 (1.07–1.71, p=0.011) and 1.48 (1.01–2.17, p=0.046) for the same respective groups. When the guidelines–based model was added as a covariate in these models, it maintained high significance with HRs around 3.88–3.98. Survival curves indicated an elevated risk for those with ferritin ≥300 ng/mL, which may point to inflammation or other processes beyond simple iron store replenishment. Another classification, the machine learning–devised model, created three categories: iron deficiency (ferritin <100 ng/mL or ferritin 100–299 ng/mL plus TSAT <20%), normal (ferritin 100–299 ng/mL plus TSAT >20%), and high ferritin (≥300 ng/mL). In "machine learning–devised model 3," patients in the high-ferritin category had an HR of 2.26 (1.31–3.88, p=0.003), a risk level that remained significant, though slightly lower, once additional covariates such as guidelines–based model were incorporated (HR about 1.84). Meanwhile, the guidelines–based model, in those same models, rose to around 5.0–5.5, reflecting persistent predictive power of the standard criteria. Kaplan–Meier curves showed that individuals classified as iron-deficient had the fastest mortality trajectory, but the high-ferritin group eventually diverged from the normal group as follow-up continued, indicating higher long-term risk.

The guidelines–based model definition offered a clear binary distinction and strongly predicted mortality risk in CHF, as shown by HR values exceeding 2.0 or 3.0. However, the clinically distribution–based model and machine learning–devised model provided a more refined gradient, identifying individuals with extremely low ferritin and TSAT <20% who might benefit from iron repletion, as well as those with excessive ferritin above 300 ng/mL who also carried worse outcomes. The inclusion of a normal category (ferritin 100–299 ng/mL plus TSAT >20%) allowed intermediate-risk individuals to be distinguished from severely deficient or high-ferritin states. Each model, despite slight variations in covariates, generated consistent findings regarding the mortality impact of either very low or very high iron parameters. Those with ferritin ≥300 ng/mL frequently experienced unfavorable outcomes, pointing to the need for further investigation into inflammatory or overload mechanisms. Conventional binary definitions may mask nuances in iron deficiency severity or elevated ferritin that signal a separate risk group [14]. Greater specificity from tertile models could inform targeted treatment, including intravenous iron supplementation, in individuals at the lower extreme, while also prompting caution in the presence of excessively high ferritin levels [14]. The comprehensive set of Kaplan–Meier curves and Cox models, together with analyses of serum iron, TIBC, ferritin, and TSAT distributions, contributed to a detailed mapping of iron-related risk in CHF populations, suggesting that customized classifications may be more informative than a single, rigid cutoff.

Discussion

The current findings suggest that iron status exerts a pronounced impact on both short- and longer-term survival in congestive heart failure (CHF). An especially prominent signal appears within the first 28 days, where mortality rates rise swiftly among individuals classified as iron deficient by standard guideline-based thresholds or grouped into the severe or very high ferritin categories. This elevated short-term risk may reflect the heightened vulnerability of hospitalized patients, many of whom exhibit acute instability, require intensive interventions, or present with overlapping complications such as shock or malignancy [1]. Indicators of iron deficiency and inflammation appear to converge during early hospitalization, implicating both functional and absolute deficits in iron as key contributors to clinical deterioration [11].

Analyses focusing on the guidelines–based model revealed consistent prognostic capability, bolstered by hazard ratios in excess of 2.0 to 3.0 within the first month. This binary definition proved

sufficient to alert clinicians to a subset of patients at risk for rapid decompensation. However, the refinement offered by tertile-based classifications allowed identification of individuals at opposing extremes: those severely deficient in iron and those with strikingly high ferritin values (≥300 ng/mL). In the context of acute or subacute heart failure exacerbations, markedly elevated ferritin may signal a robust inflammatory response or an underlying stress state associated with infection, organ dysfunction, or ischemic injury [13]. The possibility arises that excessive ferritin might underlie or reflect hepatic congestion, immune dysregulation, or ongoing catabolic processes, each of which can accelerate mortality even during the initial weeks of management [13,14].

Further evaluation of TIBC, TSAT, and ferritin distributions supports the view that inflammatory drivers can distort conventional interpretations of iron biomarkers in CHF [1,15,16]. High ferritin in a proportion of these patients likely does not signify adequate iron stores but rather an acute-phase reaction whereby ferritin is overproduced in response to inflammatory cytokines [16,17]. A cycle then emerges wherein cardiac dysfunction and subsequent reduced perfusion intensify systemic inflammation, further elevating ferritin while simultaneously limiting effective iron delivery to hematopoietic and muscular tissues. The resultant pattern of functional iron deficiency and pro-inflammatory status has the potential to compromise tissue oxygenation and myocardial energetics, factors that may become lethal within days or weeks if not promptly addressed [17]. Closer examination of short-term outcomes showed that the machine learning–devised approach produced stronger discriminatory power for mortality within the first 28 days than either the binary guidelines–based model definition or the clinically distribution–based model. In particular, "machine learning–devised model 2," which corresponded to earlier mortality analysis, indicated that those assigned to the high-ferritin category (≥300 ng/mL) experienced a hazard ratio of 2.259 (95% CI 1.314–3.883, p=0.003) compared to the reference group (ferritin <100 ng/mL or ferritin 100–299 ng/mL with TSAT <20%). This finding approached or surpassed the effects seen with the standard guideline-based criterion alone, yet it also captured a distinct high-risk subset that might otherwise have been grouped among patients presumed to have normal iron stores. By dividing individuals into iron-deficient, normal, and high-ferritin categories, the machine learning–devised model identified a clinically relevant segment whose ferritin rose above 300 ng/mL and whose early mortality risk was notably elevated. In contrast, the guidelines–based model model, although it retained strong predictive power overall, remained limited by its binary structure, making it less adaptable for distinguishing severely inflamed or overloaded phenotypes. The refined stratification permitted by the tertile based machine learning–devised model appears critical for detecting those who may harbor active inflammatory processes, hepatic congestion, or other pathology that drives ferritin to dangerously high concentrations early in the admission, thereby accelerating clinical deterioration before one month [10,18]. These findings suggest that this new model should be considered a preferred scheme for short-term risk assessment, given its capacity to highlight both genuine iron deficiency and hyperferritinemia risk, enabling more targeted interventions in the acute phase of heart failure management.

The importance of differentiating among iron status categories during this early high-risk window cannot be overstated. Tertile analysis, by distinguishing borderline from high ferritin groups, highlight the possibility that patients with 100–299 ng/mL ferritin plus TSAT above 20%—the so-called normal or borderline group—generally fare better in the first 28 days, provided they do not simultaneously harbor acute inflammatory conditions. Conversely, those with ferritin ≥300 ng/mL revealed a level of risk potentially equaling or exceeding that of iron–deficient patients. This observation frames the need to view ferritin as more than a mere index of iron stores; it also serves as an approximate gauge of inflammatory burden, which significantly influences near-term mortality

[1,18,19]. Clinically, these results advocate for a more nuanced approach to iron repletion and monitoring in CHF beyond a rigid binary threshold, extending to allowance for early detection of individuals with excessive ferritin, who might otherwise be neglected by a single definition of deficiency. The possible presence of hepatic congestion, occult infection, or systemic inflammatory disorders in this high-ferritin group should prompt detailed clinical investigations [20], since unrecognized pro-inflammatory states could lead to major complications in under a month [21]. At the opposite end, severely deficient individuals, often meeting both low ferritin and low TSAT cutoffs, may respond favorably to intravenous iron supplementation if administered early enough to support erythropoiesis and enhance tissue oxygen delivery [14]. Clinical specificity emerges as a key advantage of the tertile models. True deficiencies and inflammatory mimics can be clarified, reducing the chance that patients with overtly elevated ferritin would be misclassified as possessing robust iron stores [22]. This data therefore illuminates an interplay between iron parameters, short-term mortality risk, and underlying pathophysiological processes, suggesting that medical teams address both deficiency and inflammation [23,24]. In future work, direct measurement of inflammatory markers, as well as consideration of hepcidin or soluble transferrin receptor, may refine understanding of why a subset of patients demonstrates immediate decline despite apparently normal or high ferritin [25].

Ultimately, observations collected here propose that a deeper categorization strategy improves prognosis during a patient's most vulnerable period, including the critical first 28 days after admission for CHF. Tertile splits for ferritin or TSAT, coupled with an acute phase assessment of inflammation, seem to distinguish subsets of individuals more clearly than either a single guideline cutoff or reliance on ferritin alone. In turn, this may permit precise, time-sensitive interventions—especially intravenous iron for those in a genuinely deficient cohort, and closer examination of systemic inflammatory causes for patients whose ferritin surges beyond 300 ng/mL. Given further corroboration, this approach might lower short-term mortality by ensuring that each relevant mechanism, whether low iron availability or heightened inflammatory reactivity, receives targeted clinical attention.

Limitations

Several limitations warrant caution in interpreting these findings. The dataset is based on a retrospective review of records from a single center, Beth Israel, which may limit generalizability to other institutions or healthcare settings with different patient demographics and clinical practices. As with most retrospective analyses, causal inferences cannot be definitively established, and observed associations between iron parameters and outcomes may be influenced by unmeasured confounders. During dataset creation, some inflammatory markers were not routinely measured, making it difficult to distinguish between true iron overload and ferritin elevations driven by inflammation. Neutrophil count was initially measured, but interpreted to have no significant influence. Addressing this gap in future investigations could provide a clearer understanding of inflammatory mechanisms in iron dysregulation and heart failure progression.

Looking ahead, prospective trials that incorporate a machine learning classification would help validate its utility. Specifically, such studies might stratify participants not just by standard guideline–based iron deficiency criteria versus no deficiency, but also by the high-ferritin category to capture a distinct inflammatory or overload phenotype. This nuanced approach could better identify which subgroups benefit most from intravenous iron therapy or other targeted interventions, thereby refining treatment guidelines and potentially improving both short- and long-term outcomes in heart failure populations.

Table 1. Baseline patient demographics, laboratory values, comorbidities, medications, procedures, and mortality outcomes stratified by iron deficiency status.

Variable	Non-Iron deficiency (*n= 324)*	Iron deficiency (*n= 96)*	P-value
Demographics			
Age	73.00 (14.00)	75.00 (15.00)	0.246
Gender	139 (42.9%)	36 (37.5%)	0.409
Race			
			0.5
White	209 (64.5%)	66 (68.8%)	
Asian	9 (2.8%)	5 (5.2%)	
Hispanic	17 (5.2%)	6 (6.2%)	
Black	10 (3.1%)	2 (2.1%)	
Other	79 (24.4%)	17 (17.7%)	
Marital status			
			0.759
Married	154 (47.5%)	42 (43.8%)	
Widowed	48 (14.8%)	18 (18.8%)	
Divorced	29 (9.0%)	10 (10.4%)	
Single	75 (23.1%)	19 (19.8%)	
Other	18 (5.6%)	7 (7.3%)	
Hospitalization			
Surgical admission	53 (16.4%)	12 (12.5%)	0.449
Hospital LOS	8.94 (8.93)	7.05 (6.51)	0.041
ICU stay	196 (60.5%)	42 (43.8%)	0.005
ICU LOS	2.19 (2.65)	2.64 (3.95)	0.072
Laboratory			
Troponin	0.34 (0.89)	0.26 (0.57)	0.085
Ferritin	227.00 (544.75)	53.50 (172.25)	0
Iron	41.00 (39.25)	24.50 (21.75)	0
TIBC	259.00 (96.50)	307.50 (145.00)	0
Transferrin	199.00 (74.50)	236.50 (111.75)	0
TSAT	16.15 (16.04)	9.55 (9.07)	0
Hemoglobin	9.10 (2.92)	8.60 (2.15)	0.049
Hematocrit	27.70 (7.72)	27.30 (7.02)	0.59
RBC	3.12 (1.04)	3.29 (0.87)	0.1
RDW	15.10 (2.70)	16.20 (2.73)	0
Platelets	195.00 (94.00)	246.50 (146.50)	0
Glucose	155.50 (91.00)	145.00 (58.75)	0.034

Creatinine	1.50 (1.90)	1.30 (1.00)	0.016
eGFR	47.51 (57.26)	58.73 (45.62)	0.019
Ejection fraction	48.00 (20.00)	45.00 (20.00)	0.5
CKD-EPI Group			0.029
1	52 (16.0%)	18 (18.8%)	
2	77 (23.8%)	29 (30.2%)	
3	87 (26.9%)	30 (31.2%)	
4	59 (18.2%)	16 (16.7%)	
5	49 (15.1%)	3 (3.1%)	
Ejection fraction Group			0.193
<40	122 (37.7%)	46 (47.9%)	
41-49	35 (10.8%)	8 (8.3%)	
>50	167 (51.5%)	42 (43.8%)	
Comorbidities			
STEMI/NSTEMI	64 (19.8%)	15 (15.6%)	0.447
Chronic heart failure	160 (49.4%)	52 (54.2%)	0.479
Acute heart failure	232 (71.6%)	74 (77.1%)	0.353
Cardiac arrest	12 (3.7%)	4 (4.2%)	0.324
Valvulopathies	93 (28.7%)	36 (37.5%)	0.13
Mitral valve disease	58 (17.9%)	16 (16.7%)	0.899
Atrial valve disease	33 (10.2%)	18 (18.8%)	0.038
Atrial fibrillation	122 (37.7%)	41 (42.7%)	0.439
Hypertension	272 (84.0%)	85 (88.5%)	0.345
Hyperlipidemia	198 (61.1%)	51 (53.1%)	0.2
Peripheral vascular disease	117 (36.1%)	32 (33.3%)	0.705
Diabetes	187 (57.7%)	49 (51.0%)	0.298
Chronic kidney failure	170 (52.5%)	44 (45.8%)	0.305
Acute kidney failure	66 (20.4%)	24 (25.0%)	0.407
Mild liver disease	32 (9.9%)	5 (5.2%)	0.225
Severe liver disease	11 (3.4%)	2 (2.1%)	0.752
Malignant cancer	21 (6.5%)	8 (8.3%)	0.69
Obesity	44 (13.6%)	15 (15.6%)	0.734
Alcoholism	54 (16.7%)	14 (14.6%)	0.742
Shock	66 (20.4%)	8 (8.3%)	0.01
History of PCI	53 (16.4%)	23 (24.0%)	0.122
History of CABG	50 (15.4%)	21 (21.9%)	0.185

History of CV ME	46 (14.2%)	11 (11.5%)	0.604
Medications			
Antiplatelets	304 (93.8%)	91 (94.8%)	0.916
Aspirin	302 (93.2%)	90 (93.8%)	1
P2Y12inh	145 (44.8%)	46 (47.9%)	0.667
Anticoagulants	103 (31.8%)	34 (35.4%)	0.588
Heparin	297 (91.7%)	86 (89.6%)	0.669
Vasopressors	121 (37.3%)	21 (21.9%)	0.007
ACEi	132 (40.7%)	47 (49.0%)	0.189
ARB	45 (13.9%)	12 (12.5%)	0.858
Beta blockers	283 (87.3%)	84 (87.5%)	1
CCB	90 (27.8%)	26 (27.1%)	0.997
STATINS	295 (91.0%)	91 (94.8%)	0.333
Antidiabetic	225 (69.4%)	63 (65.6%)	0.56
Iron supplement	253 (28.3%)	134 (26.9%)	0.598
Iron supplement (IV)	113 (12.7%)	68 (13.6%)	0.664
Iron supplement (PO)	164 (18.4%)	80 (16.0%)	0.306
Procedures and Interventions			
CABG	43 (13.3%)	8 (8.3%)	0.261
PCI	70 (21.6%)	22 (22.9%)	0.895
IABP	14 (4.3%)	3 (3.1%)	0.82
Mechanical support	20 (6.2%)	3 (3.1%)	0.369
Pacemaker	36 (4.0%)	29 (5.8%)	0.168
Implantable defibrillator	14 (1.6%)	15 (3.0%)	0.108
Valve surgery	15 (4.6%)	3 (3.1%)	0.725
Dialysis	38 (11.7%)	4 (4.2%)	0.048
Ventilation	168 (51.9%)	40 (41.7%)	0.102
Mortality			
14-day Mortality	23 (7.1%)	6 (6.2%)	0.953
28-day Mortality	40 (12.3%)	9 (9.4%)	0.538
90-day Mortality	65 (20.1%)	15 (15.6%)	0.41
180-day Mortality	80 (24.7%)	21 (21.9%)	0.666
365-day Mortality	99 (30.6%)	28 (29.2%)	0.894
Hospital expiration	26 (8.0%)	7 (7.3%)	0.985

Table 2. Hazard ratios and confidence intervals for iron deficiency classifications across multiple multivariate and univariate models. Tertile models encompass multiple values as they categorize data into three distinct groups.

Iron Variable	Model 1	Model 2	Model 3	Univariate
Guidelines IDA	**2.410** (95% CI 1.965–2.956) p=0.000	**2.856** (95% CI 2.281–3.576) p=0.000	**3.050** (95% CI 2.419–3.846) p=0.000	**2.48** (95% CI 2.09–2.94) p=0.000
Ferritin Custom Tertile	*Tertile 2:* **1.486** (95% CI 1.185–1.865) p=0.001 *Tertile 3*: **1.951** (95% CI 1.350–2.820) p=0.000	*Tertile 2:* **1.366** (95% CI 1.084–1.721) p=0.009 *Tertile 3:* **1.810** (95% CI 1.239–2.642) p=0.002	*Tertile 2:* **1.353** (95% CI 1.073–1.705) p=0.011 *Tertile 3:* **1.480** (95% CI 1.009–2.172) p=0.046	**0.49** (95% CI 0.39–0.60) p=0.000
TSAT Tertile	*Tertile 2:* **1.032** (95% CI 0.829–1.284) p=0.778 *Tertile 3:* **1.322** (95% CI 1.018–1.715) p=0.037	*Tertile 2:* **1.032** (95% CI 0.827–1.287) p=0.781 *Tertile 3:* **1.304** (95% CI 1.029–1.046) p=0.050	*Tertile 2:* **1.084** (95% CI 0.865–1.359) p=0.484 *Tertile 3:* **1.290** (95% CI 0.986–1.686) p=0.064	**0.72** (95% CI 0.65–0.81) p=0.000
Final Category Tertile	*Tertile 2:* **1.611** (95% CI 0.853–3.043) p=0.142 *Tertile 3:* **2.259** (95% CI 1.314–3.883) p=0.003	*Tertile 2:* **1.638** (95% CI 0.866–3.096) p=0.129 *Tertile 3:* **2.272** (95% CI 1.317–3.918) p=0.003	*Tertile 2:* **1.651** (95% CI 0.871–3.128) p=0.125 *Tertile 3:* **1.837** (95% CI 1.062–3.177) p=0.030	**0.70** (95% CI 0.63–0.78) p=0.003



Figure 1. 365 day Kaplan-Meier survival curve on iron deficiency anemia based on current guideline definitions.



Figure 2. 365 day Kaplan-Meier survival curve on iron deficiency anemia based on a clinically distributed ferritin-based model. Group 1 (<100 ng/mL + TSAT <20%), Group 2 (Ferritin >300 ng/mL), and Group 3 (Ferritin 100–299 ng/mL + TSAT ≥20%).



Figure 3. 365 day Kaplan-Meier survival curve on iron deficiency anemia based on a machine learning–devised model. Group 1 (Ferritin <100 ng/mL or 100–299 ng/mL + TSAT <20%), Group 2 (Ferritin >300 ng/mL), and Group 3 (Ferritin 100–299 ng/mL + TSAT ≥20%).

1. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013 Apr;165(4):575-582.e3. doi: 10.1016/j.ahj.2013.01.017. Epub 2013 Feb 22. PMID: 23537975.
2. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011 Sep 13;58(12):1241-51. doi: 10.1016/j.jacc.2011.04.040. PMID: 21903058.
3. Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018 Apr;73(2):115-123. doi: 10.1080/00015385.2017.1351239. Epub 2017 Jul 21. PMID: 28730869.
4. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, Cohen-Solal A, Kindermann I, Manito N, Pfister O, Pohjantähti-Maaroos H, Taylor J, Comin-Colet J. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018 Dec;20(12):1664-1672. doi: 10.1002/ejhf.1305. Epub 2018 Oct 12. PMID: 30311713; PMCID: PMC6607482.
5. Sindone A, Doehner W, Manito N, McDonagh T, Cohen-Solal A, Damy T, Núñez J, Pfister O, van der Meer P, Comin-Colet J. Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How? J Clin Med. 2022 May 25;11(11):2976. doi: 10.3390/jcm11112976. PMID: 35683366; PMCID: PMC9181459.
6. Bhatia K, Sabharwal B, Gupta K, Lopez PD, Kaur A, Bhatia HK, Gandhi KD, Niroula S, Correa A, Birati EY, Argulian E, Fox A, Mahmood K. Clinical outcomes of intravenous iron therapy in patients with heart failure and iron deficiency: Meta-analysis and trial sequential analysis of randomized clinical trials. J Cardiol. 2024 Feb;83(2):105-112. doi: 10.1016/j.jjcc.2023.06.012. Epub 2023 Jun 26. PMID: 37380069.
7. Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol. 2021 Aug;110(8):1299-1307. doi: 10.1007/s00392-021-01837-8. Epub 2021 Mar 23. PMID: 33755777; PMCID: PMC8318946.
8. Ahmed M, Shafiq A, Javaid H, Singh P, Shahbaz H, Maniya MT, Jain H, Shakir N, Cheema HA, Ahmad A, Rehman WU, Yeap G, Nashwan AJ, Minhas AMK, Ahmed R, Fudim M, Fonarow GC. Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials. ESC Heart Fail. 2025 Feb;12(1):43-53. doi: 10.1002/ehf2.14905. Epub 2024 Jul 4. PMID: 38965691; PMCID: PMC11769671.
9. Gürgöze MT, Kardys I, Akkerhuis KM, Oemrawsingh RM, Groot HE, van der Harst P, Umans VA, Kietselaer B, Ronner E, Lenderink T, Asselbergs FW, Manintveld OC, Boersma E. Relation of Iron Status to Prognosis After Acute Coronary Syndrome. Am J Cardiol. 2022 Apr 1;168:22-30. doi: 10.1016/j.amjcard.2021.12.022. Epub 2022 Jan 16. PMID: 35045937.
10. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, van Veldhuisen DJ, Roubert B, Blackman N, Friede T, Jankowska EA, Anker SD. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023 Dec 21;44(48):5077-5091. doi: 10.1093/eurheartj/ehad586. PMID: 37632415; PMCID: PMC10733736.

11. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018 Jul 3;138(1):80-98. doi: 10.1161/CIRCULATIONAHA.118.030099. PMID: 29967232.
12. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2018 Mar 7;39(10):860. doi: 10.1093/eurheartj/ehw383. PMID: 27206819.
13. Mancardi D, Mezzanotte M, Arrigo E, Barinotti A, Roetto A. Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver. Antioxidants (Basel). 2021 Nov 24;10(12):1864. doi: 10.3390/antiox10121864. PMID: 34942967; PMCID: PMC8698778.
14. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P, Talha KM. Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 2024 Jul 9;150(2):151-161. doi: 10.1161/CIRCULATIONAHA.124.068883. Epub 2024 May 11. PMID: 38733252; PMCID: PMC11224570.
15. Lorcerie, B., Audia, S., Samson, M., Millière, A., Falvo, N., Leguy-Seguin, V., Berthier, S., & Bonnotte, B. (n.d.). Diagnosis of hyperferritinemia in routine clinical practice. La Presse Médicale, 46(12), e329–e338. https://doi.org/10.1016/j.lpm.2017.09.028
16. Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1577-83. doi: 10.1161/01.ATV.0000174126.28201.61. Epub 2005 Jun 16. PMID: 15961703.
17. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013 Mar;34(11):816-29. doi: 10.1093/eurheartj/ehs224. Epub 2012 Oct 25. PMID: 23100285; PMCID: PMC3596759.
18. Li Q, Pan Z, Zeng Y, Wang X, Li D, Yin T, Chen Q, Ling W. Associations Between Hemoglobin and Serum Iron Levels and the Risk of Mortality Among Patients with Coronary Artery Disease. Nutrients. 2024 Dec 31;17(1):139. doi: 10.3390/nu17010139. PMID: 39796572; PMCID: PMC11722639.
19. Vera-Aviles M, Kabir SN, Shah A, Polzella P, Lim DY, Buckley P, Ball C, Swinkels D, Matlung H, Blans C, Holdship P, Nugent J, Anderson E, Desborough M, Piechnik S, Ferreira V, Lakhal-Littleton S. Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway. Eur Heart J. 2024 Nov 8;45(42):4497-4508. doi: 10.1093/eurheartj/ehae359. PMID: 38917062; PMCID: PMC11544312.
20. Wang Q, Han W, Wang T, Deng H, Zhong J. The impact of iron deficiency on prognosis in stroke and non-stroke populations: A retrospective cohort study. Nutr Metab Cardiovasc Dis. 2025 Jan;35(1):103759. doi: 10.1016/j.numecd.2024.09.029. Epub 2024 Oct 3. PMID: 39571324.
21. Ciacciarelli A, Falcou A, Nicolini E, Broccolini A, Frisullo G, Abruzzese S, Scala I, Anticoli S, Testani E, Montinaro E, Ranchicchio C, De Michele M, Toni D. The prognostic role of iron deficiency in acute ischemic stroke patients: A prospective multicentric cohort study. J Neurol Sci. 2025 Feb 15;469:123371. doi: 10.1016/j.jns.2024.123371. Epub 2024 Dec 27. PMID: 39764913.

22. De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017 Jul;42:16-23. doi: 10.1016/j.ejim.2017.04.018. Epub 2017 May 18. PMID: 28528999.
23. Weidmann H, Bannasch JH, Waldeyer C, Shrivastava A, Appelbaum S, Ojeda-Echevarria FM, Schnabel R, Lackner KJ, Blankenberg S, Zeller T, Karakas M. Iron Metabolism Contributes to Prognosis in Coronary Artery Disease: Prognostic Value of the Soluble Transferrin Receptor Within the AtheroGene Study. J Am Heart Assoc. 2020 May 5;9(9):e015480. doi: 10.1161/JAHA.119.015480. Epub 2020 Apr 23. PMID: 32321351; PMCID: PMC7428563.
24. Stack AG, Mutwali AI, Nguyen HT, Cronin CJ, Casserly LF, Ferguson J. Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population. QJM. 2014 Aug;107(8):623-33. doi: 10.1093/qjmed/hcu045. Epub 2014 Mar 5. PMID: 24599805; PMCID: PMC4108849.
25. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, Inciardi RM, Clark AL. Criteria for Iron Deficiency in Patients With Heart Failure. J Am Coll Cardiol. 2022 Feb 1;79(4):341-351. doi: 10.1016/j.jacc.2021.11.039. PMID: 35086656.


Guidelines–based Model p < 0.0001
Strata
No Iron Deficiency
Iron Deficiency
1.00
0.75
0.50
0.25
0.00
Survival probability
0
100
200
300
400
Time
Number at risk
Strata
Iron Deficiency
No Iron Deficiency
719
504
435
361
0
1002
823
784
763
0
0
100
200
300
400
Time


Clinically–devised Model p < 0.0001
Strata
Group 1
Group 2
Group 3
Survival probability
1.00
0.75
0.50
0.25
0.00
0
100
200
300
400
Time
Number at risk
Strata
Group 3 664 532 510 495 0
Group 2 648 494 459 421 0
Group 1 518 377 325 276 0
0
100
200
300
400
Time


Machine learning–based Model p < 0.0001
Strata
Group 1
Group 2
Group 3
Survival probability
1.00
0.75
0.50
0.25
0.00
0
100
200
300
400
Time
Number at risk
Strata
Group 3 151 136 129 127 0
Group 2 666 534 512 497 0
Group 1 830 606 534 458 0
0
100
200
300
400
Time